This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Therapeutic Indication
Yentreve is indicated for women for the treatment of moderate to severe stress urinary incontinence (SUI).
Therapeutic Area (MeSH)
ATC Code
N06AX21
ATC Item
N/A
Pharmacotherapeutic Group
Psychoanaleptics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| duloxetine hydrochloride | N/A | duloxetine hydrochloride |
EMA Name
Yentreve
Medicine Name
Yentreve
Aliases
N/ANo risk management plan link.